Sponsor content
92 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HARUROPI ropinirole (as hydrochloride) 2 mg/24 hr transdermal drug delivery system sachet.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HARUROPI ropinirole (as hydrochloride) 4 mg/24 hr transdermal drug delivery system sachet.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HARUROPI ropinirole (as hydrochloride) 10 mg/24 hr transdermal drug delivery system sachet.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABURA abiraterone acetate 250 mg tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABURA abiraterone acetate 250 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABURA abiraterone acetate 500 mg tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABURA abiraterone acetate 500 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FEBUXOSTAT MSN febuxostat 80 mg tablet blister pack.
-
Australian public assessment report (AusPar)Briumvi (ublituximab) has been approved for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.
-
Prescription medicine registrationActive ingredients: febuxostat hemihydrate.